High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2080-2091

  Bourgon, Richard ^a   Lu, Shan ^a   Yan, Yibing ^a   Lackner, Mark R ^a   Wang, Weiru ^a   Weigman, Victor ^c   Wang, David ^b   Guan, Yinghui ^a   Ryner, Lisa ^a   Koeppen, Hartmut ^a   Patel, Rajesh ^a   Hampton, Garret M ^a   Amler, Lukas C ^a   Wang, Yulei ^a  

^a GENENTECH INC   (United States)

^b FLUIDIGM CORPORATION   (United States)

^c Expression Analysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PIK3R1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CANCER; FEMALE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; LUNG CANCER; MICROFLUIDIC MULTIPLEX POLYMERASE CHAIN REACTION; MOLECULAR DIAGNOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; GENETICS; GENOTYPING TECHNIQUE; MCF 7 CELL LINE; METABOLISM; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MCF-7 CELLS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEINS;

EID: 84898938357     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3114     Document Type: Article

References (45)

1. Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancermedicine registry. J Mol Diagn 2011;13:504-13.
2. Patel R, Tsan A, Tam R, Desai R, Schoenbrunner N, Myers TW, et al. Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PloS ONE 2012;7:e51153.
3. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small cell lung cancer. J Mol Diagn 2011;13:74-84.
4. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
5. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-85.
6. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 2012;15:171-6.
7. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013;15:234-47.
8. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
9. Johansson H, Isaksson M, Sorqvist EF, Roos F, Stenberg J, SjoblomT, et al. Targeted resequencing of candidate genes using selector probes. Nucleic Acids Res 2011;39:e8.
10. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 2010;7:111-8.
11. SinghRR, PatelKP,RoutbortMJ, ReddyNG,Barkoh BA,Handal B, et al. Clinical validation of a next-generation sequencing screen formutational hotspots in 46 cancer-related genes. J Mol Diagn 2013;15:607-22.
12. Endris V, Penzel R, Warth A, Muckenhuber A, Schirmacher P, Stenzinger A, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn 2013;15:765-75.
13. Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn 2014;16:89-105.
14. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 2013; 15:623-33.
15. Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.
16. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 2009;25:1754-60.
17. Li H, Durbin R. Fast and accurate long-read alignment with Burrows- Wheeler transform. Bioinformatics 2010;26:589-95.
18. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-9.
19. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 2010;26:873-81.
20. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics 2010;26:2069-70.
21. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4.
22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
23. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 expression in cancer and development. J Pathol 2012; 226:50-60.
24. Guo Y, Long J, He J, Li CI, Cai Q, Shu XO, et al. Exome sequencing generates high quality data in nontarget regions. BMC Genomics 2012;13:194.
25. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413-21.
26. Hosein AN, Song S, McCart Reed AE, Jayanthan J, Reid LE, Kutasovic JR, et al. Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. Lab Invest 2013;93:701-10.
27. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget 2012;3:546-58.
28. Do H, Wong SQ, Li J, Dobrovic A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin- embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem 2013;59:1376-83.
29. Daikoku T, Hirota Y, Tranguch S, Joshi AR,DeMayo FJ, Lydon JP, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008;68:5619-27.
30. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115:32-8.
31. Hayes MP, Douglas W, Ellenson LH. Molecular alterations ofEGFRand PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009;113:370-3.
32. Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006;37:1465-72.
33. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009;101:145-8.
34. Kang S, Seo SS, Chang HJ, Yoo CW, Park SY, Dong SM. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer 2008;18:1339-43.
35. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
36. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
37. Amzel LM, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-9.
38. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-91.
39. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
40. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007;318:1744-8.
41. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75.
42. Ayoola A, Barochia A, Belani K, Belani CP. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012; 30:433-46.
43. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009;4:12-21.
44. Weigelt B, Warne P, Lambros M, Reis-Filho J, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res 2013;19:3533-44.
45. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009;16:463-74.